Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies

Incyte Corporation INCY has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream to treat atopic dermatitis (AD).
Data presented at the American Academy of Dermatology Virtual Meeting Experience 2021 showed Ruxolitinib demonstrated greater improvement in all analyzed efficacy endpoints than vehicle.
A subsequent analysis of a subset of patients found higher clinical responses with ruxolitinib cream versus vehicle.
At Week 8, more patients achieved treatment success with ruxolitinib cream 0.75% and ruxolitinib cream 1.5% versus vehicle (50.0% and 59.4% versus 0%, respectively).
Patients who applied ruxolitinib cream 0.75% and ruxolitinib cream 1.5% versus vehicle achieved improvement in eczema severity at Week 8.
At Week 8, more patients achieved improvement in itch with ruxolitinib cream 0.75% and ruxolitinib cream 1.5% versus vehicle (50.0% and 61.1% versus 27.3%).
Incyte also announced updated data at Week 104 from the Phase 2 study with ruxolitinib cream in adult patients with vitiligo.
New data showed continuous improvements in facial and total body repigmentation.
Separately, an exploratory analysis evaluated the maintenance of repigmentation among patients. 75% of patients maintained total body repigmentation, and 81.3 % of patients held facial repigmentation during a follow-up duration of one to six months.
Price Action: INCY shares are up 0.8% at $84.88 on the last check Friday.